ABOS NASDAQ
Acumen Pharmaceuticals, Inc.
1W: +4.2%
1M: -11.4%
3M: -3.1%
YTD: +23.3%
1Y: +134.9%
3Y: -55.6%
$2.51
+0.02 (+0.80%)
Weekly Expected Move ±6.9%
$2
$2
$2
$2
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$152.0M
52W Range0.99-3.6
Volume381,317
Avg Volume546,106
Beta0.32
Dividend—
Analyst Ratings
Company Info
CEODaniel J. O'Connell
Employees61
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-01
Websiteacumenpharm.com
427 Park Street
Newton, VA 22902
US
Newton, VA 22902
US
434 297 1000
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Latest News
Acumen (ABOS) Q1 2026 Earnings Transcript
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Earnings Scheduled For May 12, 2026
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | A-Award | 6,060,606 | $3.30 | 2026-03-16 |
| Meisner Derek M | M-Exempt | 2,090 | $1.85 | 2026-03-06 |
| Meisner Derek M | S-Sale | 2,090 | $3.26 | 2026-03-06 |
| Meisner Derek M | M-Exempt | 2,090 | $1.85 | 2026-03-06 |
| Meisner Derek M | M-Exempt | 9,406 | $1.85 | 2026-02-27 |